Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial
Mitch Dowsett(Royal Marsden NHS Foundation Trust), Aman U. Buzdar(Nottingham City Hospital), Jack Cuzick(Queen Mary University of London), Denis Larsimont(Nottingham City Hospital), Antonio Llombart‐Cussac(Universidad Cardenal Herrera CEU), John Forbes, Emma M. Quinn(Nottingham City Hospital), Ian O. Ellis(Nottingham City Hospital), Jill Knox(Nottingham City Hospital), Fiona Knox(Nottingham City Hospital), Janine Salter(Nottingham City Hospital), Chris Wale(Nottingham City Hospital), Craig Allred(Nottingham City Hospital), Elizabeth Mallon(Nottingham City Hospital), Norman Williams(Nottingham City Hospital), Joan Houghton(Nottingham City Hospital), P J Carder(Nottingham City Hospital), Hironobu Sasano(Tohoku University), Hugh Bishop(Nottingham City Hospital), Valerie Speirs(University of Leeds)
Cited by 464
Related Papers
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
|The Lancet|2007|1.5k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
Revision of the American Joint Committee on Cancer Staging System for Breast Cancer
|Journal of Clinical Oncology|2002|1.2k